Antiplatelet Effects of Evolocumab in Patients With Peripheral Arterial Disease

Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2017

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias
This investigation will be conducted in subjects \>18 years of age with PAD. Platelet activation and aggregation, and biomarkers associated with platelet activation, oxidative stress, and inflammation will be assessed prior to initiation of study-HD statin therapy (baseline), after 8 weeks of high-dose statins and 24 hours and 8 weeks after high dose statin + evolocumab therapy
Epistemonikos ID: 5590b9a590a36f8df5e990d686af349505b349f3
First added on: May 21, 2024